Submit RFI/RFP
Request Consultation
FeaturedNew Hope for Dystrophic Epidermolysis Bullosa Patients
Dystrophic Epidermolysis Bullosa (DEB) can be a very challenging condition to live with, & with the limited treatment options available on the market, which mainly works on treating…
Newsroom
News
301 articles
Featured
FeaturedFDA educational efforts prevented young people from using e-cigarettes
In a single year, FDA educational efforts prevented about 450,000 young people from beginning to use e-cigarettes According to a research co-authored by scientists from the U.S. Food…
FeaturedTriple combination medication For cystic fibrosis, deutivacaftor, tezacaftor, and vanzacaftor are approved
The Medicines and Healthcare products Regulatory Agency (MHRA) has authorized the triple combination medication deutivacaftor/tezacaftor/vanzacaftor (brand name Alyftrek) to treat cystic fibrosis (CF) in individuals six years of…
FeaturedUnregulated pharmaceuticals used in advanced therapy present significant health hazards
The European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA) are warning the public about the risks of unregulated advanced therapy medical products (ATMPs) available to…
FeaturedmRESVIA RSV vaccine is authorized to protect individuals aged 60 and older
The Medicines and Healthcare Products Regulatory Agency (MHRA) has licensed mRNA respiratory syncytial virus (RSV) vaccine (brand name mRESVIA) to prevent individuals over the age of 60 from…
FeaturedProlonged-release opioids
The indication for post-operative pain management has been removed The indication for the management of post-operative pain has been removed from the licenses of all prolonged release opioids,…
FeaturedThe EU has introduced a new clinical trial map
A new clinical trial map is now available on the Clinical Trials Information System (CTIS) public website. The map is intended to offer patients and healthcare professionals with…
FeaturedFirst Treatment Approval for Cerebrotendinous Xanthomatosis, a Rare Lipid Storage Disease
Adults with cerebrotendinous xanthomatosis (CTX) can now be treated with Ctexli (chenodiol), which is approved by the US Food and Drug Administration. Also, it’s The first FDA-approved medication…
FeaturedThe first rapid-acting insulin biosimilar product approved by the FDA for the treatment of diabetes
For the purpose of improving glycemic control in adults and pediatric patients with diabetes mellitus, the U.S. Food and Drug Administration authorized Merilog (insulin-aspart-szjj) as a biosimilar to…
FeaturedThe FDA warns patients that while using smartphone-compatible diabetes devices, they may miss critical safety alerts due to phone settings
In order to provide vital safety alerts, the U.S. Food and Drug Administration is warning patients about a safety issue with diabetic devices that rely on smartphones, including…
FeaturedNemolizumab is approved for treating patients with prurigo nodularis and atopic dermatitis (eczema)
Nemolizumab, also known as Nemluvio, has been approved by the Medicines and Healthcare Products Regulatory Agency (MHRA) to treat moderate to severe prurigo nodularis in adults aged 18…
FeaturedThe medical imaging agent gozetotide has been approved for the diagnosis of prostate cancer
The Medicines and Healthcare products Regulatory Agency (MHRA) has authorized the use of gozetotide (marketed under the name Illuccix) in a positioning emission tomography (PET) scan, a form…
FeaturedChikungunya vaccine authorization for Adults
The MHRA has authorized the chikungunya vaccine (live) (brand name IXCHIQ) to prevent adults from chikungunya disease, which is caused by the chikungunya virus (CHIKV). CHIKV is spread…
FeaturedMHRA seeks feedback on proposed recommendations to facilitate the safe regulation of emerging personalized cancer medicines
The Medicines and Healthcare Products Regulatory Agency (MHRA) has opened a consultation on regulatory guidance for personalized mRNA cancer immunotherapies (also known as cancer vaccines). This is a…
FeaturedNew combination of drugs to treat parasitic worm infections
The EMA’s human medicines committee (CHMP) has issued a good scientific opinion on Ivermectin/Albendazole for the treatment of illnesses caused by a variety of worm parasites, including lymphatic…
Ready to simplify your journey?
Talk to our experts and get tailored solutions to help you stay compliant and move forward with confidence.
Submit RFI/RFP